JFJeremy Florence

Jeremy Florence

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeremy Florence has a total of 213 co-authors. Here are the top co-authors by number of shared publications:

  • Théo Pezel

    Hôpital Lariboisière, (Assistance Publique des Hôpitaux de Paris, AP-HP), Cardiology department, Université Paris Cité , Paris

    12 shared publications
  • Alexandre Unger

    Université Paris Cité, Department of Cardiology, University Hospital of Lariboisiere, France (J.H., S.T., T.G., A.U., J.F., J.-G.D., T.P.).

    9 shared publications
  • Jérôme Garot

    MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory (J.H., J.G., S.T., T.G., A.U., J.F., J.-G.D., T.P., Y.B.), University Hospital of Lariboisiere (AP-HP), Paris, France

    8 shared publications
  • Solenn Toupin

    Department of Cardiology, Université Paris Cité, University Hospital of Lariboisière, Assistance Publique des Hôpitaux de Paris (AP-HP) , Paris

    7 shared publications
  • Trecy Gonçalves

    Hôpital Lariboisière, (Assistance Publique des Hôpitaux de Paris, AP-HP), Cardiology department, Université Paris Cité , Paris

    7 shared publications
  • Jean-Guillaume Dillinger

    Hôpital Lariboisière, (Assistance Publique des Hôpitaux de Paris, AP-HP), Cardiology department, Université Paris Cité , Paris

    6 shared publications

Latest Publications

  • Stress CMR ischaemic burden and long-term mortality in left ventricular systolic dysfunction: a multicentre registry study

    by Alexandre Pfeffer, JérÔme Garot, Suzanne Duhamel, Philippe Garot, Francesca Sanguineti, Thomas Hovasse, StépHane Champagne, Thierry Unterseeh, Mariama Akodad, Antoinette Neylon, et al.

    Aims: Stress perfusion cardiovascular magnetic resonance (CMR) integrates the assessment of myocardial ischaemia, scar, and function. Its incremental prognostic value in patients with left ventricular (LV) systolic dysfunction remains uncertain. Methods and results: We analysed a prospective multicentre registry of consecutive patients undergoing vasodilator stress perfusion CMR at three French centres (2008–24). Patients with CMR-derived LVEF < 50% were included. The primary end point was all-cause mortality. Associations were estimated with multivariable Cox models. Incremental prognostic value of ischaemia and late gadolinium enhancement (LGE) beyond clinical factors and LVEF was assessed by likelihood ratio χ2, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Among 5977 patients (79% men; age 66 ± 12 years, mean LVEF 42 ± 7%), inducible ischaemia was present in 19% (mean extent 2.4 ± 1.2 segments). Over a median follow-up of 9 years, 1343 patients (22%) died. Ischaemic segment extent was independently associated with mortality (HR per segment 1.11; 95% CI, 1.06–1.15; P < 0.001). Adding ischaemia and LGE to clinical factors and LVEF improved model fit and reclassification (global χ2 increased from 707 to 728; NRI 0.217; IDI 0.004; all P < 0.001). Findings were consistent across LVEF subgroups (40–50% and <40%). In secondary analyses among patients with ischaemia, outcomes differed by subsequent revascularization status; these findings are observational and hypothesis-generating. Conclusion: In patients with LVEF < 50%, ischaemic burden on stress CMR is independently associated with long-term mortality beyond clinical factors, LVEF and LGE. Integrating ischaemia and scar metrics provides incremental prognostic information that may aid risk stratification using stress CMR in LV systolic dysfunction.

  • Open Access

    Current Practices and Expectations on the Environmental Impact of Interventional Cardiology: The GREEN‐CCF Study

    by Antonin Trimaille, Orianne Weizman, Louis Perrard, Charles Fauvel, Thomas de Saint Nicolas, Benjamin Marchandot, Ikram El Marzouki, Xavier Roy, Soundous M'RAbet, Sarah Laroche, et al.

    Background: While interventional cardiology has a significant environmental footprint, the level of engagement of professionals in mitigating their ecological impact remains unexplored. The GREEN‐CCF (Global Review of Environmental Expectations in Cardiac Catheterization in France) study aimed to assess current practices, perceptions, and expectations of interventional cardiology professionals in France about their environmental impact. Methods: An online survey was developed and distributed to health care professionals involved in cardiology across France. The target population included senior cardiologists, cardiologists in training, nurses, medical imaging technicians, and research staff. The questionnaire explored participants' knowledge and motivation on environmental issues, current waste management practices in catheterization laboratories, and perceived barriers and potential solutions to reducing their professional environmental footprint. Results: Among 859 participants who submitted fully completed responses, 367 (43%) were involved in interventional cardiology. Despite a high level of motivation on the environmental issues, the participants reported low levels of knowledge and perceived motivation of their centers. More than 70% of participants reported discarding materials used during procedures, including packaging, plastics, and specific materials. The most frequently cited barrier to reduce the environmental impact of interventional cardiology practices was the difficulty in changing professional behaviors (47%). The most frequently proposed actions to reduce the environmental impact of interventional cardiology were improving the durability of materials (42%), implementing standardized recommendations (33%), reducing product packaging (48%), and adopting incentives or regulatory requirements (34%). Conclusions: These findings reinforce the need of addressing environmental sustainability in interventional cardiology. While professionals are motivated and aware of the challenges, structural and institutional changes are needed to support future interventions.

  • Concomitant hypertension in hypertrophic cardiomyopathy: clinical phenotype and prognostic associations of cardiovascular magnetic resonance biomarkers

    by Jeremy Florence, Trecy GonçaLves, Solenn Toupin, Suzanne Duhamel, Philippe Garot, Julien Hudelo, Francesca Sanguineti, Thomas Hovasse, Mariama Akodad, Antoinette Neylon, et al.

    Aims: To characterize the cardiovascular magnetic resonance (CMR) phenotype of hypertensive hypertrophic cardiomyopathy (HCM) patients, assess the association between hypertension and all-cause mortality, and compare the long-term prognostic performance of CMR-derived biomarkers between hypertensive and non-hypertensive HCM patients. Methods and results: Between 2008 and 2024, all consecutive HCM patients referred for CMR from the hypertrophic cardiomyopathy-late gadolinium enhancement registry were included. The primary outcome was all-cause mortality. Clinical variables, cardiac volumes, myocardial mass, functions, and tissue characterization with late gadolinium enhancement (LGE) were assessed in all patients. The prognostic value of hypertension and CMR-derived biomarkers were assessed using survival analysis. Among 2873 patients with HCM (52 ± 8 years, 56% males), 796 (28%) had hypertension. Hypertensive HCM patients had greater LGE extent (1.1 ± 1.8 vs. 0.9 ± 1.5, P < 0.001), more LGE multiple locations (17% vs. 11%, P < 0.001), and more midwall LGE (35% vs. 28%, P = 0.001). After 1:1 propensity score matching, survival curves showed an increased risk of all-cause mortality for hypertensive HCM patients over a median follow-up of 9 years [hazard ratio (HR): 1.32, 95% confidence interval (CI): 1.04–1.69; log-rank P = 0.024]. High LGE extent (more than three segments) and septal location of LGE were independently associated with mortality in both hypertensive HCM patients (HR: 3.99, 95% CI: 2.21–7.18; P < 0.001 and HR: 1.76, 95% CI: 1.03–3.01; P = 0.039, respectively) and non-hypertensive HCM patients (HR: 4.63, 95% CI: 2.15–9.97; P < 0.001 and HR: 1.48, 95% CI: 1.02–2.15; P = 0.040, respectively). Conclusion: In a large multicenter cohort of HCM patients, concomitant hypertension was associated with increased long-term mortality, and prognostic associations of CMR-LGE biomarkers were found. These findings highlight the importance of comprehensive cardiovascular risk assessment in HCM patients.

  • Long-term Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients with Hypertension without known coronary artery disease

    by Sonia Houssany-Pissot, Jérôme Garot, Suzanne Duhamel, Solenn Toupin, Alexandre Unger, Francesca Sanguineti, Stéphane Champagne, Thierry Unterseeh, Bernard Chevalier, Jeremy Florence, et al.

    AIM: Benefits of screening coronary artery disease (CAD) using stress perfusion cardiovascular magnetic resonance (CMR) in patients with hypertension without known CAD is not well established. The aim of our study was to assess the long-term prognostic value of vasodilator stress CMR in patients with hypertension without known CAD. METHODS: Between December 2008 and January 2022, all consecutive patients with hypertension without known CAD referred for stress CMR were followed up to the occurrence of major cardiovascular events (MACE), defined as cardiovascular mortality or non-fatal myocardial infarction (MI). Cox regressions were performed to determine the prognostic value of each parameter. RESULTS: Among 2,019 patients (69 ± 12 years; 45% male) with a median follow up of 6.7 (5.9- 8.9) years, 327 had MACE (16%). Patients without ischaemia experienced a lower rate of MACE than those with ischaemia (12 versus 39%, respectively, p < 0.001). Ischaemia and unrecognised MI were both significantly associated with the occurrence of MACE (respectively, HR: 4.1, 99.5%CI: 3.0-5.7 and HR: 3.6, 99.5%CI: 2.6-5.1, both p < 0.001). After adjustment, both the extent of ischaemia and unrecognised MI were independent predictors of MACE (respectively, HR: 1.2, 99.5%CI: 1.2-1.3, and HR: 1.2, 99.5%CI: 1.1-1.3, both p < 0.001). Adding stress CMR parameters improved model discrimination and reclassification, with greatest improvements in stepwise Model (C-statistic improvement: 0.02; net reclassification improvement: 0.50; integrative discrimination index: 0.02; all p < 0.001). CONCLUSION: In patients with hypertension without known CAD, stress CMR is a long-term predictor for the incidence of MACE and offer an incremental prognostic value over traditional predictors.

  • Prognostic Impact of LGE Granularity Using CMR in End‑Stage Hypertrophic Cardiomyopathy

    by Julien Hudelo, Jérôme Garot, Solenn Toupin, Suzanne Duhamel, Francesca Sanguineti, Philippe Garot, Thomas Hovasse, Stéphane Champagne, Thierry Unterseeh, Mariama Akodad, et al.

    BACKGROUND: End-stage hypertrophic cardiomyopathy (HCM) is a distinct and advanced form of HCM, defined by a left ventricular ejection fraction P =0.02). Each LGE granularity component was independently associated with mortality after adjustment: LGE extent (hazard ratio, 2.85 [95% CI, 1.03–7.85]; P =0.02), septal location (hazard ratio, 1.73 [95% CI, 1.10–2.73]; P P <0.001). CONCLUSIONS: In this large multicenter cohort of patients with end-stage HCM, the LGE granularity model integrating LGE extent, location, and pattern provided strong and independent prognostic value.


  • Open Access

    Remote Management of Patients With Heart Failure in Medically Underserved Areas

    by Jeremy Florence, Sylvain Ploux, Clément Riocreux, F. Daniel Ramirez, Solenn Toupin, Théo Pezel, Guillaume Clerfond, Romain Eschalier


  • Stress Perfusion CMR Imaging-Guided Management and Prognosis in Patients With Suspected Coronary Heart Disease

    by Antonin Trimaille, Philippe Garot, Solenn Toupin, Francesca Sanguineti, Thomas Hovasse, Suzanne Duhamel, StépHane Champagne, Thierry Unterseeh, Mariama Akodad, Antoinette Neylon, et al.

    BACKGROUND: Identifying patients with chronic coronary syndrome who will benefit most from a coronary revascularization strategy is essential. Data on the performance of stress cardiac magnetic resonance (CMR) to guide revascularization are limited. To assess the long-term prognostic impact of stress CMR-guided revascularization strategy to predict all-cause death. METHODS: We conducted an observational study including all consecutive patients who underwent stress CMR for suspected or known chronic coronary syndrome in 3 centers in France. CMR-guided coronary revascularization was defined as any revascularization performed within 90 days following stress CMR. The primary outcome was all-cause death. RESULTS: A total of 50 701 patients were included (mean age, 64±12 years; 68.5% men). After a median follow-up of 7.2 years (interquartile range, 3.0–11.0), 3665 (7.2%) patients died. Among the 7396 patients with ischemia, 6523 (88%) underwent revascularization. Ischemia and late gadolinium enhancement (LGE) without viability were independent predictors of death (adjusted hazard ratio, 3.67 [99.5% CI, 3.15–4.27] and adjusted hazard ratio, 1.26 [99.5% CI, 1.10–1.44], respectively; P P P P =0.23). CONCLUSIONS: In this registry of consecutive patients with chronic coronary syndrome from 3 centers, stress CMR-guided revascularization was associated with a lower rate of death. The combined assessment of inducible myocardial ischemia and LGE may help to select patients most suitable for revascularization.


  • Open Access

    Prognostic Impact of Recreational Drug Use on 1-Year Outcomes in NSTEMI and STEMI Patients

    by Michael Aboujaoude, Nefissa Hamache, Jean Guillaume Dillinger, Antonin Trimaille, Claire Bouleti, Clément Delmas, Guillaume Schurtz, Sonia Houssany-Pissot, Reza Rossanaly Vasram, Guillaume Bonnet, et al.


  • Open Access

    Rational and design of EACVI-MMVD study: an international registry on multimodality imaging for mixed and multiple valvular heart disease

    by Alexandre Unger, Giulia Elena Mandoli, Danilo Neglia, Elena Romero Dorta, Nobuyuki Kagiyama, Sonia Borodzicz-Jazdzyk, Eirini Velegraki, Augustin Coisne, Begüm Uygur, Andreea Afana, et al.

    Aims: Multiple and mixed valvular heart disease (MMVD) are frequent situations in clinical practice. Despite a high prevalence, comprehensive insights into their clinical presentation, management strategies, impact of multimodality imaging, and outcomes are not well established, due to a lack of dedicated studies. Methods and results: The ‘EACVI-MMVD Study’ will be a large prospective, multicentre, observational cohort study led by the Heart Imagers of Tomorrow of the European Association of Cardiovascular Imaging (EACVI). It will assess the proportion, management, and prognosis of MMVD over a 1-year period of follow-up. All consecutive patients diagnosed with MMVD using transthoracic echocardiography will be recruited over a 6-month recruitment period in 88 centres from 24 different countries. Baseline evaluation will be determined by physicians and encompass the whole spectrum of multimodality imaging including transthoracic and transoesophageal echocardiography, stress echocardiography, computed tomography, and cardiovascular magnetic resonance. Centres will have the opportunity to send cardiovascular imaging data for core laboratory analysis and to extend recruitment throughout a 5-year follow-up period. Conclusion: The EACVI-MMVD study will be the largest international multicentre study evaluating the prevalence of MMVD in clinical routine and determining the impact of multimodality cardiovascular imaging in MMVD patients. Clinical Trial Registration: NCT06235385 URL: https://classic.clinicaltrials.gov/ct2/show/NCT06235385


  • The prognostic value of expiratory carbon monoxide level for outcome prediction after myocardial infarction

    by Antoine Léquipar, Manveer Singh, Jean Guillaume Dillinger, Antonin Trimaille, Claire Bouleti, Clément Delmas, Guillaume Schurtz, Sonia Houssany-Pissot, Reza Rossanaly Vasram, Edouard Gerbaud, et al.

    Aims: To assess the prognostic value of expiratory carbon monoxide (CO) levels in patients admitted for myocardial infarction (MI). Methods and results: In this prospective study, expiratory CO levels were measured upon admission in consecutive patients hospitalized for MI across 39 centres. The primary outcome was 1-year all-cause death. Secondary outcomes included 1-year major adverse cardiac events (MACEs: cardiovascular death and recurrent MI) and in-hospital major adverse events (MAEs: death, severe ventricular arrhythmia, cardiogenic shock, and the need for mechanical ventilation). The prognostic value of expiratory CO levels was further evaluated using machine learning (ML) analysis. Among 717 patients (64 ± 13 years; 75% males; 33% active smokers; 43% ST-elevation MI), elevated expiratory CO levels (>11 ppm) were found in 79 patients (11%). Patients with elevated CO levels had a higher rate of 1-year all-cause mortality compared with those without (16.5% vs. 5.2%, P < 0.001). Elevated CO levels were independently associated with 1-year all-cause death across various adjustment models: comorbidities [odds ratio (95% confidence interval): 3.6 (1.7–7.5)], clinical parameters of in-hospital severity [4.5 (2.3–8.8)], and respiratory parameters [6.3 (3.1–12.8)]. Elevated CO levels were also independently associated with a significant increase in 1-year MACEs and in-hospital MAEs. Machine learning analysis identified CO level as one of the most important predictors of adverse events, compared with other known prognosticators. Conclusion: This is the first study to demonstrate that elevated expiratory CO levels upon admission are independently associated with an increased risk of 1-year all-cause mortality, 1-year MACEs, and in-hospital MAEs in patients hospitalized for MI.